PBPK Model Simulations for Inhaled Tigecycline Dose Optimization

A synthetic dataset from a physiologically-based pharmacokinetic (PBPK) modeling study by Hyunseo Park, published in March 2026. The research simulates tigecycline exposure in plasma, epithelial lining fluid (ELF), and major organs to optimize inhaled dosing for Mycobacterium abscessus pulmonary infections. It includes model-based predictions for efficacy and safety thresholds across multiple dosing scenarios.

Use Cases

• Analyze simulated longitudinal exposure profiles in plasma and ELF to compare inhaled versus intravenous dosing efficacy.
• Evaluate predicted plasma AUC0-24 values against the gastrointestinal adverse event threshold of 6.87 mg·h/L for safety assessment.
• Use simulated steady-state bone concentrations to assess risk relative to the defined bone toxicity threshold from rat studies.
• Compare predicted peak concentrations in ELF from model simulations to effective exposure levels identified in murine infection models.

Strengths

• Model qualified using experimental data from mice, rats, and literature reports in humans, demonstrating cross-species applicability.
• Simulations provide exposure predictions for multiple key sites: systemic circulation, ELF, and other major organs.
• Dataset is openly licensed under CC BY 4.0.

Limitations

• Data is synthetic, generated entirely from model simulations, not from direct clinical or experimental measurements.
• The dataset scope is limited to a single study's modeling output, contained within a 901.4 KB PDF file.
• Temporal coverage and sample size (rows) for the underlying simulation data are not specified.

Provenance

Source

Figshare, authored by Hyunseo Park.

Collection Method

Generated via physiologically-based pharmacokinetic (PBPK) modeling, leveraging preclinical data from mouse and rat studies and human literature.

Time Range

null

Freshness

null

Geography

null